We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.


We are advancing innovative science and transformative medicines for people living with inflammatory and autoimmune diseases, including a portfolio of first in class programs and innovative development approaches across inflammatory bowel disease (IBD), respiratory, and rheumatological diseases.

Partnering opportunities we are looking for:

  • Gastroenterology, Respiratory, Rheumatology
    • Innate, Adaptive, Fibrosis, Tolerance and Tissue Regeneration Targets

Example partnerships

Promedior – acquisition to further develop and commercialise PRM-151, a first-in-class recombinant human pentraxin-2 molecule targeted at preventing and potentially reversing fibrosis

Rheos – collaboration, option and license agreement with Roche to discover, develop and commercialise novel therapeutics in the field of immunometabolism

Parvus – collaboration to develop, manufacture and commercialise novel Navacim therapeutics to drive tolerance in inflammatory bowel disease, autoimmune liver disease and celiac disease

Your dedicated partnering leads in Immunology

Enza di Modugno, Head of Immunology & Infectious Diseases, Pharma Partnering

Luca Piali, Search & Evaluation Lead Immunology & Infectious Diseases, Pharma Partnering

Rebecca Kunder, Search & Evaluation Lead Immunology & Infectious Diseases, Pharma Partnering